JP2013536828A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536828A5
JP2013536828A5 JP2013526490A JP2013526490A JP2013536828A5 JP 2013536828 A5 JP2013536828 A5 JP 2013536828A5 JP 2013526490 A JP2013526490 A JP 2013526490A JP 2013526490 A JP2013526490 A JP 2013526490A JP 2013536828 A5 JP2013536828 A5 JP 2013536828A5
Authority
JP
Japan
Prior art keywords
transdermal therapeutic
therapeutic system
solid transdermal
matrix
protective film
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013526490A
Other languages
English (en)
Japanese (ja)
Other versions
JP6104800B2 (ja
JP2013536828A (ja
Filing date
Publication date
Priority claimed from DE102010040299A external-priority patent/DE102010040299A1/de
Application filed filed Critical
Publication of JP2013536828A publication Critical patent/JP2013536828A/ja
Publication of JP2013536828A5 publication Critical patent/JP2013536828A5/ja
Application granted granted Critical
Publication of JP6104800B2 publication Critical patent/JP6104800B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013526490A 2010-09-06 2011-09-02 結晶化を阻害する保護フィルムを有する経皮治療システム(剥離ライナー) Expired - Fee Related JP6104800B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102010040299.0 2010-09-06
DE102010040299A DE102010040299A1 (de) 2010-09-06 2010-09-06 Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
PCT/EP2011/065204 WO2012031985A1 (de) 2010-09-06 2011-09-02 Transdermale therapeutische systeme mit kristallisationsinhibierender schutzfolie (release liner)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016161929A Division JP2016216500A (ja) 2010-09-06 2016-08-22 結晶化を阻害する保護フィルムを有する経皮治療システム(剥離ライナー

Publications (3)

Publication Number Publication Date
JP2013536828A JP2013536828A (ja) 2013-09-26
JP2013536828A5 true JP2013536828A5 (enExample) 2017-02-02
JP6104800B2 JP6104800B2 (ja) 2017-03-29

Family

ID=44653285

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013526490A Expired - Fee Related JP6104800B2 (ja) 2010-09-06 2011-09-02 結晶化を阻害する保護フィルムを有する経皮治療システム(剥離ライナー)
JP2016161929A Pending JP2016216500A (ja) 2010-09-06 2016-08-22 結晶化を阻害する保護フィルムを有する経皮治療システム(剥離ライナー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016161929A Pending JP2016216500A (ja) 2010-09-06 2016-08-22 結晶化を阻害する保護フィルムを有する経皮治療システム(剥離ライナー

Country Status (33)

Country Link
US (2) US8557279B2 (enExample)
EP (1) EP2613771A1 (enExample)
JP (2) JP6104800B2 (enExample)
KR (1) KR20130114127A (enExample)
CN (1) CN103079549B (enExample)
AP (1) AP3586A (enExample)
AR (1) AR082907A1 (enExample)
AU (1) AU2011298892B2 (enExample)
BR (1) BR112013005305A2 (enExample)
CA (1) CA2810103C (enExample)
CL (1) CL2013000636A1 (enExample)
CO (1) CO6690753A2 (enExample)
CR (1) CR20130098A (enExample)
CU (1) CU24172B1 (enExample)
DE (1) DE102010040299A1 (enExample)
DO (1) DOP2013000053A (enExample)
EA (1) EA032575B1 (enExample)
EC (1) ECSP13012477A (enExample)
GT (1) GT201300062A (enExample)
IL (2) IL224980A (enExample)
MA (1) MA34581B1 (enExample)
MX (1) MX2013002602A (enExample)
MY (1) MY162768A (enExample)
NZ (1) NZ607630A (enExample)
PE (2) PE20131138A1 (enExample)
PH (1) PH12013500429A1 (enExample)
SG (2) SG10201506927TA (enExample)
TN (1) TN2013000087A1 (enExample)
TW (1) TWI576245B (enExample)
UA (1) UA110217C2 (enExample)
UY (1) UY33590A (enExample)
WO (1) WO2012031985A1 (enExample)
ZA (1) ZA201301389B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH674618A5 (enExample) 1987-04-02 1990-06-29 Ciba Geigy Ag
JP3238389B2 (ja) 1988-10-27 2001-12-10 シエーリング アクチエンゲゼルシヤフト ゲストデン含有の経皮適用のための薬剤
NZ240358A (en) 1990-10-29 1994-09-27 Alza Corp Transdermal contraceptive device comprising (as active agents) an estrogen and a gestodene together with a skin permeation enhancer
US5512292A (en) 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4210711A1 (de) 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4405899A1 (de) * 1994-02-18 1995-08-24 Schering Ag Mittel zur transdermalen Applikation enthaltend Desogestrel
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
DE19629468A1 (de) * 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme
DE19827732A1 (de) * 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
DK1242012T3 (da) 1999-11-24 2010-04-26 Agile Therapeutics Inc Forbedret transdermalt præventionsmiddelafgivelsessystem og fremgangsmåde
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
TWI287455B (en) 2000-12-05 2007-10-01 Noven Pharma Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use
EP1216699A1 (de) 2000-12-21 2002-06-26 Schering Aktiengesellschaft Transdermalsystem enthaltend ein hochpotentes Gestagen
US20030165547A1 (en) * 2001-05-18 2003-09-04 Elisabeth Picard-Lesboueyries Cosmetic uses of 3beta-acetoxy-7-oxo-DHEA
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
MEP14008A (en) * 2003-02-21 2010-06-10 Bayer Schering Pharma Ag Uv stable transdermal therapeutic plaster
UA89766C2 (en) * 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
US8668925B2 (en) * 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
KR101168449B1 (ko) * 2003-12-12 2012-07-25 바이엘 파마 악티엔게젤샤프트 침투 증진인자가 필요없는 호르몬의 경피 전달계
MX2007004315A (es) * 2004-10-08 2008-03-11 Noven Pharma Dispositivo para suministro transdermico de farmaco que incluye un respaldo oclusivo.
DE102004062182B4 (de) 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (de) 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
JP2012504609A (ja) * 2008-10-06 2012-02-23 マイラン・テクノロジーズ,インコーポレイテッド アモルファスロチゴチン経皮システム

Similar Documents

Publication Publication Date Title
JP2014065727A5 (enExample)
ES2528650T3 (es) Sistema terapéutico transdérmico que comprende buprenorfina
ES2299630T3 (es) Emplastos para la profilaxis y/o el tratamiento de disfunciones o trastornos del crecimiento de las uñas.
JP2017538735A5 (enExample)
JP5658353B2 (ja) 経皮吸収製剤
CN103096882B (zh) 含有多奈哌齐的经皮吸收制剂
JP2012504609A5 (enExample)
JP2015500329A5 (enExample)
JP2010510260A5 (enExample)
CA2861782C (en) Transdermal therapeutic system with a low tendency to spontaneously crystallize
JP2010521525A (ja) 非晶質薬物の経皮系、製造方法、および安定化
RU2014111255A (ru) Трансдермальная терапевтическая система для гидрохлорида 5-аминолевулиновой кислоты
JP6556873B2 (ja) 経皮吸収製剤
EA201591124A1 (ru) Трансдермальная система доставки
JP2014508810A5 (enExample)
JP2016522792A (ja) リバスチグミンを含む、経皮薬物送達システム
US20130281944A1 (en) Transdermal therapeutic system (tts) comprising rotigotine
ES2745154T3 (es) Sistema de tratamiento transdérmico que contiene buprenorfina y un alfa-hidroxiácido
JP2008538753A5 (ja) 骨の老化または骨粗しょう症の治療または予防用組成物
NZ607630A (en) Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
WO2005049004A1 (ja) 貼付剤
ES2992643T3 (en) Esketamine-suspension-tts
JP2015522012A (ja) ロチゴチンを含有した経皮吸収製剤(Transdermalcompositioncomprisingrotigotine)
JP6002055B2 (ja) 貼付剤
RU2016149799A (ru) Трансдермальная терапевтическая система, содержащая лавандовое масло